Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.

@article{Couraud2014NoninvasiveDO,
  title={Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.},
  author={S{\'e}bastien Couraud and Felipe Vaca-Paniagua and St{\'e}phanie Villar and Javier Oliver and Tibor Schuster and H{\'e}l{\`e}ne Blanch{\'e} and Nicolas Girard and Jean Tredaniel and Laurent Guilleminault and Radj Gervais and Nathalie Prim and M. Vincent and Jacques Margery and S{\'e}bastien Lariv{\'e} and Pascal Foucher and Bernard Duvert and Maxime Vall{\'e}e and F. Le Calvez-Kelm and James Mckay and Pascale Missy and Franck Morin and G{\'e}rard Zalcman and Magali Olivier and Pierre Jean Souquet},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 17},
  pages={4613-24}
}
PURPOSE Tumor somatic mutation analysis is part of the standard management of metastatic lung cancer. However, physicians often have to deal with small biopsies and consequently with challenging mutation testing. Circulating free DNA (cfDNA) is a promising tool for accessing the tumor genome as a liquid biopsy. Here, we evaluated next-generation sequencing (NGS) on cfDNA samples obtained from a consecutive series of patients for the screening of a range of clinically relevant mutations… CONTINUE READING